Navigation Links
Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
Date:2/9/2011

PRINCETON, N.J., Feb. 9, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTC Bulletin Board: PRTT) announced today that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

Ram Sesha, Protect's Chief Operating Officer, said, "We are very happy to see Protect's programs are innovative and promising enough to attract someone like Grunenthal, a leader in pain drug discovery and research."

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy. Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (OTC Bulletin Board: PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceutical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
2. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
5. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
6. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
7. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
8. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
9. Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project (QTDP) Grant Under the U.S. Patient Protection and Affordable Care Act of 2010
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/9/2017)... June 9, 2017 AirXpanders, Inc. (ASX: AXP) ... the design, manufacture, sale and distribution of the AeroForm® ... progress of its commercial roll-out in the ... more than one hundred (100) medical institutions and health ... offers a needle-free alternative for women who choose reconstructive ...
(Date:6/8/2017)...  Less than a month ago, amateur hackers executed ... including hospital networks, in over 150 countries. ... largest online extortion attempts ever recorded. With the increasing ... imperative that providers understand where the risks lie, and ... and many other very real cyber threats.  ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The ... will ultimately do significant harm to people with all chronic conditions, including mental ... it leaves in place the Affordable Care Act (ACA) requirement that insurers cover ...
(Date:6/23/2017)... NY (PRWEB) , ... June 23, 2017 , ... ... certified plastic surgeon practicing in Newburgh, New York, has recently begun offering three ... Committed to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is ...
(Date:6/23/2017)... Washington, D.C. (PRWEB) , ... June 23, 2017 ... ... temperature during cooking is essential, and two new videos highlight the importance of ... Extension Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of ... United States. In 2012, the Biggert-Waters Act was enacted to reflect the actual ...
Breaking Medicine News(10 mins):